CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Psyence Biomedical Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Psyence Biomedical Ltd
121 Richmond Street West Penthouse
Suite 1300
TORONTO, ON  M5H 2K1  Canada Ticker: PBMPBM
This company was Merged or Acquired on 1/25/2024.
This is a Subsidiary, click here for the Parent Company
Business Summary
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board MichaelJordaan 52 3/1/2021 3/1/2021
Chief Executive Officer, Director MarcBalkin 47 3/1/2021 3/1/2021
Chief Financial Officer JurgenVan De Vyver 34 6/12/2023 6/12/2023
3 additional Officers and Directors records available in full report.

Business Names
Business Name
NCAC
NCACU
PBM
Psyence Biomed II Corp.

General Information
Outstanding Shares: 19,925,659 (As of 1/25/2024)
Shareholders: 5
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024